Simvastatin
Phase 3UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing Remitting Multiple Sclerosis
Conditions
Relapsing Remitting Multiple Sclerosis
Trial Timeline
Oct 1, 2005 → —
NCT ID
NCT00242268About Simvastatin
Simvastatin is a phase 3 stage product being developed by Biogen for Relapsing Remitting Multiple Sclerosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00242268. Target conditions include Relapsing Remitting Multiple Sclerosis.
What happened to similar drugs?
20 of 20 similar drugs in Relapsing Remitting Multiple Sclerosis were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00242268 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Relapsing Remitting Multiple Sclerosis